Clinical trials
Recurrent High Grade Glioma clinical trials
Below are recruiting recurrent high grade glioma clinical trials, each written for real people, not researchers. We’re tracking 78 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT06763965Enrolling by invitationPhase 1/Phase 2
BioTTT001 for recurrent high-grade glioma
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
Beijing, Chaoyang DistrictAges 18 years+ - NCT04590664RecruitingPhase 1/Phase 2
Verteporfin for recurrent EGFR-mutant glioblastoma
This trial tests verteporfin (Visudyne), given through a vein, for recurrent glioblastoma that has an EGFR mutation or increased EGFR. It aims to shrink or slow the tumor after standard treatment has already been tried.
Atlanta, GeorgiaAges 18 years+ - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+ - NCT04299191RecruitingPhase 1/Phase 2
LAM561 for children with advanced brain or solid tumors
This Phase 1/2 study tests a medicine called LAM561 in children whose cancer is advanced and not responding to standard treatment. The goal is to see if the drug is safe and can shrink or control tumors in this setting.
Little Rock, ArkansasAges Up to 18 years - NCT07488754Recruiting
Targeted radiation therapy for new glioma (grade 3-4)
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
Warsaw, PolandAges 18–80 - NCT07179328RecruitingPhase 1
Focused ultrasound for glioblastoma during standard chemo
This trial tests whether focused ultrasound can safely open the blood-brain barrier to help your chemotherapy work better. It is for people with glioblastoma who have already completed standard surgery and chemo-radiation and are now on maintenance chemo.
Toronto, OntarioAges 18–85 - NCT04254419RecruitingPhase 1
Natural killer cell injections in the brain tumor area
This early-phase trial tests injections of lab-grown immune cells directly into (or near) a brain tumor. It aims to see if the treatment is safe and can help control recurrent, progressive, or resistant CNS tumors.
Columbus, OhioAges 1–39 - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Birmingham, AlabamaAges 18 years+ - NCT06703255RecruitingPhase 1/Phase 2
Testing HX301 for advanced high-grade glioma
This trial tests an experimental drug called HX301 for people with high-grade gliomas (fast-growing brain tumors). It is for patients whose tumor has come back after temozolomide chemo, or for those with newly diagnosed glioblastoma that has been surgically removed. The study aims to see if HX301 can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT06910306Recruiting
DaRT alpha radiation for recurrent glioblastoma
This trial tests a device called DaRT that delivers alpha radiation directly to a recurrent glioblastoma tumor. It may help patients who cannot have surgery and have a single, small tumor regrowth.
Scottsdale, ArizonaAges 18–85 - NCT04065776Recruiting
Proton therapy that avoids the hippocampus for slow brain tumors
This study tests a proton radiation plan designed to spare the hippocampus (a memory area) in children and teens with certain low-grade brain tumors. It may help deliver treatment to the tumor while reducing unwanted brain effects.
Rochester, MinnesotaAges 6–21 - NCT04547777RecruitingPhase 1
Early Phase brain tumor treatment with implanted device and injections
This Phase 1 study tests a new brain-tumor treatment in people with recurrent (coming back) high-grade glioma (brain cancer). The study uses injected medicine along with an implanted tumor device and aims to find whether the treatment is safe and can shrink or control tumors.
Durham, North CarolinaAges 18 years+ - NCT06585527RecruitingPhase 1
TS-2021 for recurrent malignant brain tumors
This trial tests the safety and effectiveness of a new drug called TS-2021 for people whose high-grade brain tumor has come back after initial treatment. It may be an option if you previously had surgery, radiation, or chemotherapy and are now facing a recurrence.
Beijing, Beijing MunicipalityAges 18–65 - NCT06917885RecruitingPhase 1
CUE-102 for Recurrent Glioblastoma: A Safety Study
This study tests an experimental drug, CUE-102, for people with recurrent glioblastoma. It aims to see if the drug is safe and how well it works. You may be eligible if your tumor has come back once, you have a specific genetic marker (HLA-A*0201), and you are not on other treatments.
Boston, MassachusettsAges 18 years+ - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07441707RecruitingPhase 1
Tovorafenib for Japanese children and young adults with brain tumors
This study tests an experimental medicine called tovorafenib for children and young adults (6 months to 25 years) with Japanese ancestry whose low-grade brain tumors have returned or grown after prior treatment. The medicine targets tumors with a specific BRAF genetic change.
KanagawaAges 6 months–25 years - NCT03122197RecruitingEarly Phase 1
Letrozole for recurrent high-grade brain tumors
This early-phase study tests letrozole, a hormone-blocking medicine, in adults with recurrent high-grade gliomas. The goal is to see if it can help control the tumor and is safe enough to study further.
Cincinnati, OhioAges 18 years+ - NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT05607407RecruitingPhase 2
Methimazole for progressive glioblastoma after planned surgery
This Phase 2 trial studies whether methimazole, a medicine that affects the thyroid system, can help control progressive glioblastoma (a fast-growing brain tumor) after surgery. It looks at safety and how well the treatment works when given after your surgical plan.
Cleveland, OhioAges 18 years+
Hear when a new Recurrent High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent high grade glioma?
- Yes. Clin2 currently lists 78 recruiting recurrent high grade glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent high grade glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent high grade glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.